Drugs / XULANE
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | XULANE | — | 2014-04-16 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04624867 | Nov 2020 → Jan 2022 | — | Noven Pharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xulane | “HP-1050 transdermal system (HP-1050) in comparison to XULANE patch” NCT04624867 ↗1“HP-1050 and Xulane will be administered simultaneously.” NCT04624867 ↗ |